Pilatus Biosciences to Present Solid Tumor Cancer Trial Data at ESMO 2026
Pilatus Biosciences will present results from its Phase 1 trial of PLT012 for solid tumor cancers at the ESMO 2026 congress. The presentation focuses on ongoing research in cancer treatment.
Pilatus Biosciences announced it will present data from its ongoing Phase 1 clinical trial for PLT012. The presentation will be delivered as a "Trials-in-Progress Poster" at the European Society for Medical Oncology (ESMO) Congress in 2026.
The trial focuses on PLT012 as a potential treatment for solid tumor cancers. This marks a step in the drug's development pipeline for oncology indications.
Pilatus Biosciences is a biotechnology company dedicated to developing novel therapeutics for cancer patients. The company aims to address unmet medical needs in the field of oncology.
The ESMO Congress is a major international conference for medical professionals specializing in cancer research and treatment, showcasing advancements in the fight against the disease.